To date, there are six ongoing studies involving patients with CKD on PD treated with SGLT-2 inhibitors, and their objectives are (1) evaluating the safety and mechanisms by which SGLT-2 inhibitors can preserve RKF; (2) determining if these drugs can reduce peritoneal glucose absorption and, consequently, have an effect on UF; and (3) evaluating the cardio-nephroprotective effects of SGLT-2 inhibitors in the subgroup of patients undergoing RRT. The gene discussed is SLC5A2; the disease is chronic kidney disease.